The Future of Precision Medicine: Bispecific Antibodies How are bsAbs revolutionizing drug development? 🔸Two targets, one molecule 🔸Enhanced therapeutic precision 🔸Reduced drug resistance 🔸Novel treatment strategies Leading the charge in: 🔸Cancer immunotherapy 🔸Autoimmune diseases 🔸Infectious diseases 🔸Ophthalmology 🔸Cardiovascular disorders With 20 approved therapies and more in late-stage trials, bsAbs are transforming how we treat complex diseases. 👉 Learn more about these revolutio
0:07
The Future of Precision Medicine: Bispecific Antibodies How are bsAbs revolutionizing drug development? 🔸Two targets, one molecule 🔸Enhanced therapeutic precision 🔸Reduced drug resistance 🔸Novel treatment strategies Leading the charge in: 🔸Cancer immunotherapy 🔸Autoimmune diseases 🔸Infectious diseases 🔸Ophthalmology 🔸Cardiovascular disorders With 20 approved therapies and more in late-stage trials, bsAbs are transforming how we treat complex diseases. 👉 Learn more about these revolutio
已浏览 28 次2024年11月27日
FacebookGenScript
Dr. Nicole Angel, oncologist from Southern Cancer Center, joined WKRG on The Doctor is In to discuss bispecific antibodies. | WKRG
7:24
Dr. Nicole Angel, oncologist from Southern Cancer Center, joined WKRG on The Doctor is In to discuss bispecific antibodies. | WKRG
已浏览 33 次2023年11月1日
FacebookWKRG
R/R DLBCL Case Panel Discussion: Overview and Differences of Bispecific Antibodies
R/R DLBCL Case Panel Discussion: Overview and Differences of Bispecific Antibodies
2025年6月1日
vumedi.com
In our recent webinar, Improving Patient Outcomes via Novel Bispecific Antibody Treatment Options, we explored how this class of therapies is transforming care for B-cell non-Hodgkin lymphomas, including follicular lymphoma (FL).​ ​Dr Jonathan Cohen (Winship Cancer Institute, Emory University) explains how bispecific antibodies represent another important treatment option for patients to consider with their oncologists.​ ​He was joined by Dr Mitchell Smith, FLF's CMO, and Ferris, a patient advoc
1:11
In our recent webinar, Improving Patient Outcomes via Novel Bispecific Antibody Treatment Options, we explored how this class of therapies is transforming care for B-cell non-Hodgkin lymphomas, including follicular lymphoma (FL).​ ​Dr Jonathan Cohen (Winship Cancer Institute, Emory University) explains how bispecific antibodies represent another important treatment option for patients to consider with their oncologists.​ ​He was joined by Dr Mitchell Smith, FLF's CMO, and Ferris, a patient advoc
已浏览 1139 次2025年8月18日
FacebookFollicular Lymphoma Foundation
How does it work | bispecific antibodies This is from years ago, but pretty good for an introductory video in 60 seconds:
1:02
How does it work | bispecific antibodies This is from years ago, but pretty good for an introductory video in 60 seconds:
已浏览 3059 次4 个月之前
x.comJack Prescott
Bispecific antibodies work very effectively to treat myeloma, but they also increase the risk of infection, explains IMF CMO Dr. Joe Mikhael. This episode of Myeloma Made Simple is supported by Pfizer; watch the full video now at www.myeloma.org/node/11751 #MyelomaMadeSimple | International Myeloma Foundation
0:50
Bispecific antibodies work very effectively to treat myeloma, but they also increase the risk of infection, explains IMF CMO Dr. Joe Mikhael. This episode of Myeloma Made Simple is supported by Pfizer; watch the full video now at www.myeloma.org/node/11751 #MyelomaMadeSimple | International Myeloma Foundation
已浏览 2695 次2025年6月14日
FacebookInternational Myeloma Foundation
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
8 个月之前
reachmd.com
13:28
What’s New in Pancreatic Cancer? Early Data from the TWINPEAK Bispecific Antibody Study Join GI oncology experts Dr. Anwaar Saeed (University of Pittsburgh), Dr. Zev Wainberg (UCLA), and Dr. Teresa Macarulla (Vall d’Hebron Institute of Oncology, Spain) as they discuss early findings from the TWINPEAK trial, presented at American Society of Clinical Oncology GI 2026 in San Francisco. ✅ Early efficacy and safety data of Spevatamig, a first-in-class bispecific T-cell engager targeting Claudin 18.2
已浏览 9651 次9 个月之前
FacebookOncoDaily
0:49
In this episode of The Hematologist podcast, Contributing Editor Tycel Phillips, MD, speaks with Arnon Kater, MD about the emerging role of bispecific antibodies in the treatment of Richter transformation. Listen now: https://t.co/LG9sN2nLdv #Hematology
已浏览 2068 次4 个月之前
x.comASH
3:06
𝐁𝐈𝐎 𝟐𝟎𝟐𝟔: @NEOKBio CEO Mayank Gandhi discusses the benefits of having a bispecific approach to antibody-drug conjugates. #BIO2026Full video: https://t.co/EPTRZs2MaH
已浏览 1995 次4 个月之前
x.comBiotechTV
ASCO® 2025 Insights: Bispecific Antibodies in Thoracic Malignancies
2025年7月14日
vumedi.com
6:14
AI for Bispecific Antibody Strategy Development | Subha B. Basu, PhD/MBA posted on the topic | LinkedIn
1 个月前
linkedin.comSubha B. Basu, PhD/MBA
Some bispecific antibody therapies are given through an infusion into a vein, while others are injected under the skin. Find out more about how each bispecific antibody for Multiple Myeloma is different and key questions to discuss with your healthcare team to ensure your https://t.co/WzUFBA7gK1
已浏览 224 次1 个月前
x.comMM in the Know
6:45
'Guided missile' for cancer: Akeso on its bispecific antibody-drug strategy
1 个月前
MSNCNBC
0:28
Regeneron on Instagram: "Bottlenecks can slow promising science from the lab to the clinic. To address this, we developed a technology platform to create bispecific antibodies with customizable precision. Reflecting one of the five principles of innovation from George D. Yancopoulos, Co-Founder, President and Chief Scientific Officer, it's about driving rigor, repeatability, and real-world impact at scale for our patients. Watch the full video in the link in our bio."
已浏览 3837 次8 个月之前
Instagramregeneron
CRS and Neurotoxicity Management in Multiple Myeloma: Practical Clinical Approaches and Real-World Pearls for Bispecific Antibodies
11 个月之前
vumedi.com
1:30
Bispecific Antibodies vs CAR T-Cells: Mechanistic and Practical Distinctions | CancerNetwork
10 个月之前
cancernetwork.com
NEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate Pipeline
6 个月之前
neokbio.com
New Treatment Option for Gastric Cancer: Bispecific Antibody Drug Conjugates (ADCs) | CTOAM | Cancer Treatment Options Management
6 个月之前
linkedin.com
52:35
Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
已浏览 61 次2025年8月5日
bilibili百奥赛图
1:04:03
Common Light Chain Antibody Library for Bispecific ADC R&D
已浏览 83 次2025年8月5日
bilibili百奥赛图
1:13
إيه هي تقنية Bispecific Antibodies؟ التقنية دي بتجمع بين نوعين من الأجسام المضادة عشان تستهدف الخلايا السرطانية بشكل أكتر دقة وفعالية. شوف الفيديو مع دكتور حسام الأشطوخي علشان تعرف أكتر عن التقنية دي وكيف بتساعد في علاج الأورام. | مركز الدكتور حسام الأشطوخي لعلاج الأورام
已浏览 2.1万 次2025年9月30日
Facebookمركز الدكتور حسام الأشطوخي لعلاج الأورام
2:04
Patients with relapsed or refractory diffuse large B-cell lymphoma have a poor prognosis. Glofitamab, a novel T-cell–engaging bispecific antibody, might improve outcomes in these patients. New research findings are summarized in a short video. https://nej.md/3UGxXF7 | The New England Journal of Medicine
已浏览 2182 次2022年12月14日
FacebookThe New England Journal of Medicine
55:39
普健生物——双特异性抗体靶点介绍与结构设计 专题讲座
已浏览 1417 次2022年12月9日
zhihu.comAtaGenix普健生物
1:26
Amokrane Aya on Instagram‎: "تعد الأجسام المضادة ثنائية التخصص (Bispecific Antibodies - bsAbs) نقطة هامة في العلاج البيولوجي والطب المناعي، حيث تختلف عن الأجسام المضادة التقليدية بقدرتها الفريدة على الارتباط بهدفين مختلفين في وقت واح و تستعمل في حالات الإفلات المطورة من قبل الأورام السرطانية المقاومة"‎
已浏览 21.4万 次8 个月之前
Instagramdr_amokrane_aya_
1:01
CAR T Cell vs. Bispecific Antibodies: Myeloma Treatment In this webinar, Dr. Omar Nadeem discusses the latest research on early treatment strategies, including CAR-T and combination therapy. | HealthTree for Multiple Myeloma
已浏览 3.5万 次2025年6月30日
FacebookHealthTree for Multiple Myeloma
0:53
The top 10 most impactful myeloma breakthroughs in CAR T-cell therapy and bispecific antibodies from ASH. Watch now: https://mmsm.link/4qeZrlU #ASH25 #IMFASH25 #ASKTHEIMF | International Myeloma Foundation
已浏览 9093 次9 个月之前
FacebookInternational Myeloma Foundation
1:09
This is big. More than 85% of trial participants remained in remission 3 years later. Learn about a major bispecific antibody breakthrough. #ASH25 #IMFASH25 #ASKTHEIMF #mmsm | International Myeloma Foundation
已浏览 7647 次9 个月之前
FacebookInternational Myeloma Foundation
0:32
How do we turn complex technology challenges into simpler solutions for patients? By designing with intention to remove bottlenecks and build platforms that can adapt across diseases. This approach is guided by our co-founder, President, and Chief Scientific Officer, George D. Yancopoulos, whose five principles of radical innovation shape how we think, design, and build. Created to cut through complexity, our proprietary Veloci-Bi® technology allows for production of bispecific antibodies, which
已浏览 2.8万 次9 个月之前
FacebookRegeneron
0:07
Honored to present our CUBIC study on real-world outcomes in bispecific antibodies in relapsed/refractory follicular lymphoma. In a cohort of 99 patients, these therapies appear similarly as safe and effective as demonstrated in clinical trial populations. Manuscript coming soon!
已浏览 1780 次4 个月之前
x.comJessica Allen
0:14
Once someone's been treated for several weeks with bispecific antibodies, we can sometimes back off a bit, explains IMF CMO Dr. Joe Mikhael. This episode of Myeloma Made Simple is supported by Pfizer; watch the full video now at www.myeloma.org/node/11751 #MyelomaMadeSimple | International Myeloma Foundation
已浏览 3663 次2025年6月17日
FacebookInternational Myeloma Foundation
1:16
Transitioning BCMA-directed bispecific antibodies into community practice has the potential to improve access and convenience, but requires appropriate infrastructure, training, and multidisciplinary coordination. Watch the full video here: https://t.co/oid3HHdp9x#MultipleMyeloma #mmsm #myeloma #MedEd @MilesPrince4
已浏览 619 次3 个月之前
x.comMultiple Myeloma Hub
1:50
Early clinical trial data suggest that combining new bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for patients with large B-cell lymphoma. Dr. Jay Spiegel presented these finding at the American Society of Hematology Annual Meeting. Many patients experience a pattern in which therapies work quickly but often fail to provide long-term control. This challenge led researchers, led by senior author and our ver
已浏览 1806 次10 个月之前
FacebookSylvester Comprehensive Cancer Center
0:17
RT @UCCancerCenter: At #ASCO2026, Michael Bishop, MD, discussed rare and unique long-term toxicities of bispecific antibodies in multiple m…
已浏览 576 次4 个月之前
x.comUChicagoCancerCenter
BM219: A Phase 2 Trial of an Inhaled Bispecific Single-Domain Antibody in Mild-to-Moderate COVID-19 – Archyde
2025年7月18日
archyde.com
An In Vivo Technique to Track Bispecific Antibody-Induced T Cell Trafficking to Tumors
2025年7月26日
jove.com
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
9 个月之前
reachmd.com
Lupus Advances in Novel Biologics, Bispecific Antibodies, and CAR T Cell Therapy
5 个月之前
vumedi.com
Refining Bispecific Antibody Engineering
2025年5月19日
labroots.com
icIEF & Mass Photometry for Bispecific Antibody Analysis | Bio-Techne
6 个月之前
bio-techne.com
20:21
Characterization of Antibody Variants in Process Development - Waters Videos
2025年6月2日
bcvp0rtal.com
1:58
Expert Highlights Patient-Centered Advantages of Bispecific Antibody Therapy | Pharmacy Times
9 个月之前
pharmacytimes.com
Cstone Pharmaceuticals Announces One of Its Autoimmune and Inflammation Pipeline Cs2015 (Ox40l/Tslp Bispecific Antibody) At Acaai 2025
2025年9月14日
marketscreener.com
1:24
When it comes to CAR T-cell therapy or bispecific antibodies, how important are specific mutations when deciding on these therapies? Dr. Joseph Mikhael, IMF Chief Medical Officer, answers in this short clip. Watch the full myeloma Q&A: https://www.myeloma.org/node/11711 #AsktheIMF | International Myeloma Foundation
已浏览 1758 次2025年5月11日
FacebookInternational Myeloma Foundation
6:45
'Guided missile' for cancer: Akeso on its bispecific antibody-drug strategy
1 个月前
CNBC
Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple Myeloma | CancerNetwork
1 个月前
cancernetwork.com
Lymphoma With CNS Involvement: Clinical Outcomes With CD3xCD20 Bispecific Antibodies
4 个月之前
vumedi.com
Bispecific Antibody-Drug Conjugates (BsADCs)
已浏览 376 次2025年8月5日
bilibili百奥赛图
6:40
ASCO Merus Ph I study of MCLA-145, a bispecific CD137 and PD-L1 in solid tumors
已浏览 156 次2024年8月26日
bilibiliDrSssssssss
0:09
Genmab and our partner @abbvie announced topline results from a phase 1/2 study for our investigational #bispecific antibody in relapsed/refractory large B-cell #lymphoma. Read the latest here: https://t.co/xn5OQLwTMR
2022年4月14日
x.comGenmab
1:38
Bispecific Antibodies
2018年3月30日
hubpages.com
0:46
In this video, Dr. Susan Bal, a hematologist and oncologist at the University of Alabama at Birmingham, explains bispecific antibodies. Click link in our bio for MORE about multiple myeloma treatments! #multiplemyeloma #multiplemyelomaawareness #mmsm #cancerstories #thepatientstory #cancer #bloodcancer #myeloma *Thank you to GSK for its support of our patient education program! The Patient Story retains full editorial control over all content. | The Patient Story
已浏览 231 次2024年6月24日
FacebookThe Patient Story
26:06
Diffuse Large B-Cell Lymphoma—From Early CAR T Referral to Bispecific Antibodies and Next-Generation Cellular Therapies
1 个月前
vumedi.com
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
2025年1月7日
financialpost.com
0:22
✨Join us for an insightful webinar on The Future of Lymphoma Therapy – 2025 Update! 🩺 Get the latest on non-Hodgkin lymphoma treatments like CAR T-cell therapy and bispecific antibodies from lymphoma experts Dr. Andrew Evens from Rutgers Cancer Institute and Dr. Tycel Phillips from City of Hope. 📅 Date: Wednesday, January 29, 2025 🕒 Time: 3 p.m. PST / 6 p.m. EST 🌐 Register Now: https://tinyurl.com/378jzwz2 💬 Don’t miss this chance to hear from medical experts as they share their unique pers
已浏览 141 次2025年1月17日
FacebookThe Patient Story
0:43
COMING TO #ASH24? 🧬 Discover key differences between current and emerging bispecific antibodies for R/R FL at #ASH24! 💊 Enhance your skills in managing therapies and AEs. Build confidence in patient-centered strategies for optimal care. 📍 http://ms.spr.ly/6180oEjOe | Medscape Oncology
已浏览 25 次2024年12月6日
FacebookMedscape Oncology
Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL | OncLive
2025年7月11日
onclive.com
1:01
Immatics on Instagram: "Today, we announced updated Phase 1a dose escalation data from both product candidates in our TCR Bispecifics (TCER®) pipeline, IMA402 PRAME Bispecific and IMA401 MAGEA4/8 Bispecific, as well as next steps for clinical development. We will also host a conference call and webcast today, November 12, 2025, at 8:30 am EST / 2:30 pm CET. 👇🏼👇🏼👇🏼 Read the full announcement and find the webcast link in the “Immatics Press Releases” page, linked in bio. #DataRelease #PressR
已浏览 658 次11 个月之前
Instagramimmatics
0:17
Kathy Goss (@kathyhgoss) on X
已浏览 685 次4 个月之前
x.comKathy Goss
Clinical Activity of MCLA-158 (Petosemtamab), an IgG1 Bispecific Antibody Targeting EGFR and LGR5, in Advanced HNSCC
2023年5月22日
vumedi.com
展开
静态缩略图占位符